NCT01613768View on ClinicalTrials.gov

Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 8, 2012

Primary Completion Date

August 23, 2017

Study Completion Date

August 23, 2017

Conditions
Recurrent Salivary Gland CancerStage IVA Salivary Gland CancerStage IVB Salivary Gland CancerStage IVC Salivary Gland Cancer
Interventions
DRUG

eribulin mesylate

Given IV

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT01613768 - Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer | Biotech Hunter | Biotech Hunter